The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBr.small Co.2 Regulatory News (BSC)

Share Price Information for Br.small Co.2 (BSC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 56.50
Bid: 55.50
Ask: 57.50
Change: 0.00 (0.00%)
Spread: 2.00 (3.604%)
Open: 56.50
High: 56.50
Low: 56.50
Prev. Close: 56.50
BSC Live PriceLast checked at -
British Smaller Companies VCT 2 is an Investment Trust

To create a portfolio that blends a mix of businesses operating in established industries with those that offer opportunities in the application and development of innovation.

Find out More

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Half Yearly Report

29 Aug 2012 11:17

RNS Number : 9912K
British Smaller Companies VCT2 Plc
29 August 2012
 



British Smaller Companies VCT 2 plc

Unaudited Interim Results and Interim Management Statement

 

For the 6 months ended 30 June 2012

 

British Smaller Companies VCT 2 plc ("the Company") today announces its unaudited interim results for the six months to 30 June 2012.

 

Chairman's Statement

 

I am pleased to report another very strong trading period for your Company in the six months to 30 June 2012 with further portfolio value growth of 8.6% and £10.1 million of new funds raised through a new share subscription.

 

On 13 August 2012 we reported the successful trade sale of Primal Pictures to an undisclosed buyer which delivered a value uplift of £0.95 million since 31 December 2011 and an overall cash return of 2.2 times original investment cost.

 

I am pleased to follow this with news of another successful exit from the portfolio, with Sirigen Group Limited completing a trade sale to Becton, Dickinson & Company on 24 August 2012, which has resulted in crystallised additional value growth of £0.66 million since the start of the year and an overall cash return of 2.8 times original investment cost. These results are particularly pleasing in light of the challenging economic times and prove that it is still possible to make strong returns by backing small businesses with a competitive advantage in their niche market.

 

The recent Offer for Subscription which closed on 5 April 2012 raised a total of £10.1 million net of costs, consequently the Company remains well placed to take advantage of the growing investment activity levels

 

The Total Return to Shareholders as at 30 June 2012 is100.0 pence per Ordinary share, representing a year to date increase of 1.5 pence from the 98.5 pence per Ordinary share at 31 December 2011 and an increase of 4.1 pence over the 12 month period since 30 June 2011. Total Return to Shareholders includes cumulative dividends paid which now stands at 32.0 pence per Ordinary share.

 

The Net Asset Value at 30 June 2012 is 68.0 pence per Ordinary share (68.5 pence per Ordinary share at 31 December 2011), which reflects an increase in the portfolio value of 2.3 pence per Ordinary share and gains on disposals of 0.2 pence per Ordinary share offset by the payment of a 2.0 pence per Ordinary share final dividend paid in May 2012 and the dilutive impact of new shares issued.

 

Interim Management Report

 

Over the six month period to 30 June 2012 the Company has seen an increase in investment levels with a total of £2.5 million invested (compared to £1.2 million in the 6 months to 30 June 2011), £2.3 million into 3 new opportunities and £0.21 million into 2 existing portfolio companies. The first of the new opportunities was £0.70 million invested in January 2012 as part of the management buyout of the retail display group Displayplan Holdings Limited from its US parent company. In March 2012 £0.3 million was invested as part of the £2 million buyout of Selima Limited, a supplier of payroll and expenses software predominantly to public sector customers. Finally in April 2012 £1.26 million was invested into Seven Technologies holdings Limited, a Northern Irish engineering business that specialises in developing and manufacturing bespoke electronics and communications applications for operation in inhospitable environments.

 

The first follow-on deal was a £0.06 million investment into the fluorescent labelling technology group, Sirigen Group Limited, as part of a £1 million internal growth round in February 2012. Secondly, £0.15 million was invested into AIM-listed EKF Diagnostics Holdings plc in March 2012, which reported strong progress towards building a profitable international diagnostics group.

 

Investment rates have continued to increase following the period end, with an additional £1.97 million having been invested to date. A follow-on investment of £0.9 million has been made into Immunobiology Limited, as part of a £3.0 million round, including new external investors, to take its innovative vaccine programme into human clinical trials. An additional £0.16 million has been invested into Vianet Group plc which has made good progress in diversifying its remote monitoring solutions for the brewing, fuel solution and remote vending sectors. A new investment of £0.13 million has been made into Hargreaves Services plc which is involved in sourcing and supply of solid fuel for the UK power industry. A new investment of £0.78 million has been made into Insider Technologies Limited to fund the buyout of the company, which provides monitoring and scheduling software for the financial service and security sectors.

 

Against the backdrop of on-going economic challenges, the Company remains focused on building a strong and diversified portfolio, whilst also looking to improve levels of portfolio income. Significant positive steps have been made in this regard. Excluding the new investments and a slight decrease in the value of gilts, the underlying value of the opening portfolio has grown by £0.93 million (8.6%) over the six months to 30 June 2012.

 

Whilst there were no significant realisations from the portfolio in the year, the Company has received £0.54 million of proceeds following the full and partial disposal of investments in 5 portfolio companies and an additional £0.05 million of deferred consideration in relation to the sale of DXS Limited in 2009. Following the period end the Company has however completed two significant realisation through the trade sales of Primal Pictures Limited and Sirigen Group Limited. Primal Pictures Limited, a supplier of 3D human anatomical images and training materials, has been sold to an undisclosed international publishing group. This has resulted in £1.82 million, at completion, of cash proceeds to the Company, a profit of £0.95 million over the 31 December 2011 valuation and resulting in a cash multiple of 2.2 on cost over the life of the investment. Sirigen Group Limited, a supplier of innovative fluorescent marking technology, has been sold to the US-based diagnostics group Becton, Dickinson & Company. At completion this delivered £1.45 million of cash proceeds, an increase of £0.66 million on the 31 December 2011 value and a cash multiple of 2.8x cost, with further deferred consideration anticipated.

 

Other portfolio companies have made good progress. Digital Healthcare Limited has made positive progress in integrating its 2011 acquisition of retinal screening supplier, Orion Imaging Limited, and has started to deliver the expected synergy benefits. Port operator RMS Group Holdings Limited has completed the refinancing of all remaining institutional loans ahead of schedule. Strong progress has been made for the Company's two retail rollout investments with branded kitchen manufacturer Harvey Jones Limited increasing to 25 stores and coffee bar operator Bagel Nash Limited completing a profitable first year and highlighting locations for its first new shops. The £3.0 million further funding round into Immunobiology Limited is a significant positive step in commercialising its vaccine technology although the low pricing of this round (from which the Company has also benefited through its recent investment) has resulted in a value fall of £0.51 million for the existing holding.

 

There has been no change to the principal risks and uncertainties facing the Company since the publication of the financial statements for the year ended 31 December 2011. In summary, the principal risks are:

·; Investment and strategic;

·; Loss of approval as a Venture Capital Trust;

·; Regulatory;

·; Reputational;

·; Operational;

·; Financial;

·; Market risk; and

·; Liquidity risk.

 

Full details of the principal risks can be found in the financial statements for the year ended 31 December 2011 on page 24, a copy of which can be found at www.yfmep.com

 

Financial Results

 

The result for the six months ended 30 June 2012 produced a revenue profit before tax of £47,000 and a capital profit before tax of £802,000 (2011: profit of £2,000 and profit of £473,000 respectively). It is pleasing to see a strong improvement in the aggregate value of investments over the six months to 30 June 2012 of £881,000. The income from the portfolio of £258,000 also represents an increase of £80,000 on the same period in 2011 and the Fund Manager will continue to make investments to gradually improve the income generation from the portfolio.

 

The movement in Net Asset Value per Ordinary share is as follows:

Pence/Ordinary share

31 December 2011

68.5

Dividends paid in period

(2.0)

Net Increase in value

1.5

30 June 2012

68.0

 

 

Following the new funds raised this year, cash and investment in gilts at 30 June 2012 totalled £13.0 million (June 2011: £6.85 million), representing 50% (June 2011: 43%) of Net Asset Value before taking account of any interim dividend. The Board considers that in the short term this is sufficient to support the current portfolio and to continue its investment strategy in selective new opportunities.

 

Shareholder Relations

 

The last six months has seen the Company's investment capacity increase through the issue of 14,983,236 shares pursuant to the recently closed "Offer for Subscription", raising £10.1 million net of costs. In addition the Company issued 20,611 shares as part of the dividend reinvestment scheme on 22 May 2012. The Board believes that the coming 12-24 months will see increasing investment opportunities and will continue to consider the opportunity to raise further funding in the months ahead to enable the Company to take advantage of this and continue to build a strong, balanced portfolio.

 

The Board remains committed to the objective of achieving a consistent dividend stream. Following the 2011 year end a dividend of 2.0 pence per Ordinary share was paid on 22 May 2012, this commitment has been continued in these interim results with your Board determining that an interim dividend of 2.5 pence per Ordinary share will be paid on 26 October 2012 to Shareholders on the register as at 28 September 2012.

 

Regulatory and Other Matters

Following the issue of the Draft Finance Bill 2012 on 29 March 2012 investments undertaken by the Company will be subject to new legislation.

 

Following EU approval and the Finance Bill gaining Royal Assent, changes have been made to the "qualifying company" limits effective from 6 April 2012. These are summarised as follows:

 

·; the employee limit will increase from 50 to 250 for investee companies;

·; an increase in the size threshold of gross assets to £15 million before investment from £7 million; and

·; that the maximum amount that an investee company can receive from VCTs and other State Aid sources will now be £5 million.

 

Funds raised by VCTs after 5 April 2012 may not be used to finance buy-outs or otherwise to acquire existing shares.

 

The Company does not currently have any funds to which the buy-outs rule applies.

 

Overall the Board believes these changes are a positive step and are expected to significantly increase the level and scale of investment opportunities available to the Company over the coming years.

 

Outlook

 

The last six months have seen a continuation of the difficult market conditions of recent years and it is likely that the UK economy will experience a sustained period of very low growth. In spite of this many of the portfolio companies have delivered improved results and have been able to take advantage of changes in their markets. We hope to see this trend continue as economic conditions gradually improve.

 

Whilst the year ahead will continue to present challenges we are optimistic about the Company's ability to take advantage of the upcoming opportunities. The hesitant approach from the banks and changes in EU restrictions on qualifying investments should both lead to an increase in the volume and scale of investment opportunities in the future.

 

The Board remains of the opinion that the forthcoming period will see many good investment opportunities, both for the portfolio businesses and for new investments. It was with this in mind that we increased the investment capacity of the Company and we will consider the opportunity to further increase funds in the coming months.

 

 

Richard Last

29 August 2011

 

 

Statement of Comprehensive Income

For the 6 months ended 30 June 2012

 

 

Unaudited

6 months ending 30 June 2012

Unaudited

6 months ending 30 June 2011

 

Notes

 

Revenue

£000

 

Capital

£000

 

Total

£000

 

Revenue

£000

 

Capital

£000

 

Total

£000

Gain on disposal of investments

-

76

76

-

7

7

Gains on investments held at fair value

-

876

876

-

576

576

Income

2

258

-

258

178

-

178

Administrative expenses:

Fund Management fee

(50)

(150)

(200)

(36)

(110)

(146)

Other expenses

(161)

-

(161)

(140)

-

(140)

(211)

(150)

(361)

(176)

(110)

(286)

Profit before taxation

47

802

849

2

473

475

Taxation

3

-

-

-

-

-

-

Profit for the period attributable to equity Shareholders

 

47

802

849

2

473

475

Total comprehensive income for the period attributable to equity Shareholders

 

47

802

849

2

473

475

 

Basic and diluted earnings per Ordinary share

 

5

0.13p

2.24p

2.37p

0.01p

2.32p

2.33p

 

The Total column of this statement represents the Company's Statement of Comprehensive Income, prepared in accordance with International Financial Reporting Standards as adopted by the European Union ('IFRSs'). The supplementary Revenue and Capital columns are prepared under the Statement of Recommended Practice 'Financial Statements of Investment Trust Companies and Venture Capital Trusts' ('SORP') 2009 published by the Association of Investment Companies.

 

Balance Sheet

As at 30 June 2012

 

 

Notes

 

Unaudited

6 months ended 30 June

2012

 

£000

Unaudited

6 months ended 30 June

2011

 

£000

Audited

year

ended 31 December

2011

 

£000

Assets

Non-current assets

Investments

13,044

8,684

10,209

Fixed income government securities

918

2,839

1,618

Financial assets at fair value through profit or loss

13,962

11,523

11,827

Trade and other receivables

68

281

65

14,030

11,804

11,892

Current assets

Trade and other receivables

315

173

242

Cash and cash equivalents

12,085

4,009

4,076

12,400

4,182

4,318

Liabilities

Current liabilities

Trade and other payables

(426)

(98)

(228)

Net current assets

11,974

4,084

4,090

Net assets

26,004

15,888

15,982

Shareholders' equity

Share capital

3,942

2,412

2,426

Share premium

12,993

4,346

4,427

Capital redemption reserve

88

88

88

Merger reserve

5,525

5,525

2

Other reserve

2

2

5,525

Capital reserve

2,120

2,964

2,630

Investment holding losses

(2,778)

(4,135)

(3,665)

Special reserve

4,112

4,352

4,255

Revenue reserve

-

334

294

Total Shareholders' equity

26,004

15,888

15,982

 Net Asset Value per Ordinary share

6

68.0p

68.0p

68.5p

 

Signed on behalf of the Board

 

Richard Last

Chairman

29 August 2012

Unaudited Statement of Changes in Equity

For the 6 months ended 30 June 2012

 

 

 

 

 

 

Share capital

 

Share premium account

 

 

Merger reserve

 

 

 *Other reserves

Capital reserve

Investment holding gains (losses) reserve

 

Special

reserve

 

Revenue reserve

 

 

Total

equity

£000

£000

 

£000

£000

£000

£000

£000

£000

£000

At 31 December 2010

 

1,785

810

5,525

90

3,587

(4,763)

4,463

332

11,829

Revenue return for the period

-

-

-

-

-

-

-

2

2

Capital expenses

-

-

-

-

(110)

-

-

-

(110)

Investment holding loss on investments held at fair value

 

-

 

-

 

-

 

-

 

-

 

576

-

 

-

 

576

Realisation of investments in the period

 

-

 

-

 

-

 

-

 

7

 

-

-

 

-

 

7

Total comprehensive income for the period

 

-

 

-

 

-

 

-

(103)

576

-

2

475

Issue of share capital

627

3,582

-

-

-

-

-

-

4,209

Issue costs

-

(46)

-

-

-

-

-

-

(46)

Purchase of own shares

-

-

-

-

-

-

(111)

-

(111)

Dividends

-

-

-

-

(468)

-

-

-

(468)

Total transactions with shareholders

627

3,536

-

-

(468)

-

(111)

-

3,584

Realisation of prior year investment holding losses

 

-

 

-

 

-

 

-

 

(52)

 

52

-

 

-

 

-

At 30 June 2011

 

2,412

4,346

5,525

90

2,964

(4,135)

4,352

334

15,888

Revenue return for the period

-

-

-

-

-

-

-

(40)

(40)

Capital expenses

-

-

-

-

(149)

-

-

-

(149)

Investment holding gain on investments held at fair value

 

-

 

-

 

-

 

-

-

536

-

 

-

536

Gain on disposal of investments in the period

 

-

 

-

 

-

 

-

218

-

-

 

-

218

Total comprehensive income for the period

-

-

-

-

69

536

-

(40)

565

Issue of share capital

13

280

-

-

-

-

-

-

293

Issue costs

-

(204)

-

-

-

-

-

-

(204)

Purchase of own shares

-

-

-

-

-

-

(97)

-

(97)

Issue of Shares - DRIS

1

5

-

-

-

-

-

-

6

Dividends

-

-

-

-

(469)

-

-

-

(469)

Total transactions with shareholders

14

81

 

-

 

-

(469)

-

(97)

-

(471)

Realisation of prior year investment holding gains

 

-

 

-

 

-

-

66

(66)

-

-

-

At 31 December 2011

 

2,426

4,427

5,525

90

2,630

(3,665)

4,255

294

15,982

 

 

 

 

Unaudited Statement of Changes in Equity

For the 6 months ended 30 June 2012

 

 

 

 

 

 

Share capital

 

Share premium account

 

 

Merger reserve

 

 

 *Other reserves

Capital reserve

Investment holding gains (losses) reserve

 

Special

reserve

 

Revenue reserve

 

 

Total

equity

£000

£000

 

£000

£000

£000

£000

£000

£000

£000

At 31 December 2011

 

2,426

4,427

5,525

90

2,630

(3,665)

4,255

294

15,982

Revenue profit for the period

-

-

-

-

-

-

-

47

47

Capital expenses

-

-

-

-

(150)

-

-

-

(150)

Investment holding gain on investments held at fair value

-

-

-

-

-

876

-

-

876

Gain on disposal of investments in the period

-

-

-

-

76

-

-

-

76

Total comprehensive income for the period

-

-

-

-

(74)

876

-

47

849

Issue of ordinary Share capital

1,514

9,149

-

-

-

-

-

-

10,663

Issue of Shares - DRIS

2

11

-

-

-

-

-

-

13

Issue costs of Ordinary shares

-

(594)

-

-

-

-

-

-

(594)

Purchase of own shares

-

-

-

-

-

-

(143)

-

(143)

Dividends

-

-

-

-

(425)

-

-

(341)

(766)

Total transactions with Shareholders

1,516

8,566

-

-

(425)

-

(143)

(341)

9,173

Realisation of prior year investment holding losses

-

-

-

-

(11)

11

-

-

-

At 30 June 2012

 

3,942

12,993

5,525

90

2,120

(2,778)

4,112

-

26,004

 

* Other reserves include the capital redemption reserve and treasury reserve, which are non-distributable.

Statement of Cash Flows

For the 6 months ended 30 June 2012

 

 

 

 

Unaudited

6 months ended 30 June

2012

 

£000

 

Unaudited

6 months ended 30 June

2011

 

£000

 

 

Audited year ended 31 December

2011

 

£000

Net cash inflow (outflow) from operating activities

17

(40)

(174)

Cash flows from investing activities

Purchase of financial assets at fair value through profit or loss

(2,467)

(2,352)

(3,970)

Proceeds from sale of financial assets at fair value through profit or loss

1,238

2,307

4,276

Deferred consideration

48

-

322

Net cash (used in) from investing activities

 

(1,181)

(45)

628

Cash flows from financing activities

Issue of Ordinary shares

10,663

4,210

4,502

Cost of Ordinary shares

(594)

(46)

(250)

Purchase of own shares

(143)

(111)

(208)

Dividends paid

(753)

(468)

(931)

Net cash from financing activities

 

9,173

3,585

3,113

Net increase in cash and cash equivalents

8,009

3,500

3,567

Cash and cash equivalents at the beginning of the period

4,076

509

509

Cash and cash equivalents at the end of the period

 

12,085

4,009

4,076

 

Notes to the Unaudited Financial Statements

 

1. General information, basis of preparation and principal accounting policies

 

These half year statements have been approved by the directors whose names appear at note 8, each of whom has confirmed that to the best of his knowledge:

·; The Interim Management Report includes a fair review of the information required by rules 4.2.7 and 4.2.8 of the Disclosure Rules and the Transparency Rules.

·; The half year statements comply with IAS 34 'Interim financial reporting' and the Disclosure and Transparency Rules of the Financial Services Authority.

 

The half year statements are unaudited and have not been reviewed by the auditors pursuant to the Auditing Practices Board (APB) guidance on Review of Interim Financial Information. They do not constitute full financial statements as defined in section 435 of the Companies Act 2006. The comparative figures for the year ended 31 December 2011 do not constitute full financial statements and have been extracted from the Company's financial statements for the year ended 31 December 2011. Those accounts were reported upon without qualification by the auditors and have been delivered to the Registrar of Companies.

 

The accounting policies and methods of computation followed in the half year statements are the same as those adopted in the preparation of the audited financial statements for the year ended 31 December 2011, except as noted below.

 

The financial statements for the year ended 31 December 2011 were prepared in accordance with the International Financial Reporting Standards (IFRSs) as adopted by the European Union and those parts of the Companies Act 2006 applicable to companies reporting under IFRS. Where guidance set out in the Statement of Recommended Practice 'Financial Statements of Investment Trust Companies and Venture Capital Trusts' issued by the Association of Investment Companies in January 2009 ("SORP") is consistent with the requirements of IFRS, the financial statements have been prepared in compliance with the recommendations of the SORP.

 

Other standards and interpretations have been issued which will be effective for future reporting periods but have not been adopted early in these financial statements. These include IFRS9, IFRS10, IFRS11, IFRS12, IFRS13, and IFRIC20. A full impact assessment has not yet been completed in order to assess whether these new standards will have a material impact on the financial statements.

Notes to the Unaudited Financial Statements 

 

 

 

2. Income

Unaudited

6 months ended

30 June

2012

 

£000

Unaudited

6 months ended

30 June

2011

 

£000

Income from investments

- Dividends from unquoted companies

3

3

- Dividends from AIM quoted companies

22

20

25

23

- Interest on loans to unquoted companies

147

77

- Fixed interest Government securities

11

69

Income from investments held at fair value through profit or loss

183

169

Interest on bank deposits

75

9

258

178

Notes to the Unaudited Financial Statements

 

 

3. Taxation

 

Unaudited 6 months ended 30 June 2012

Unaudited 6 months ended 30 June 2011

 

Revenue

£000

 

Capital

£000

 

Total

£000

 

Revenue

£000

 

Capital

£000

 

Total

£000

 

Profit before taxation

 

47

 

802

 

849

 

2

 

473

 

475

 

Profit before taxation multiplied by standard small company rate of corporation tax in UK of 20% (2010: 20%)

 

 

9

 

 

160

 

 

169

 

 

-

 

 

95

 

 

95

Effect of:

UK dividends received

(5)

-

(5)

(5)

-

(5)

Non taxable profits on investments

-

(200)

(200)

-

(117)

(117)

Excess management expenses

(4)

40

36

5

22

27

Tax (credit)/ charge

-

-

-

-

-

-

 

The Company has no provided, or unprovided, deferred tax liability in either year.

 

Deferred tax assets in respect of losses have not been recognised as management do not currently believe that it is probable that sufficient taxable profits will be available against which the assets can be recovered.

 

Due to the Company's status as a venture capital trust, and the continued intention to meet the conditions required to comply with Chapter 3 Part 6 of the Income Tax Act 2007, the Company has not provided deferred tax on any capital gains or losses arising on the revaluation or realisation of investments.

 

Notes to the Unaudited Financial Statements

 

4. Dividends

 

Amounts recognised as distributions to equity holders in the period:

 

Unaudited

6 months ended

30 June 2012

Unaudited

6 months ended

30 June 2011

Audited

Year ended

31 December 2011

 

Revenue

£000

 

Capital

£000

 

Total

£000

Revenue

£000

 

Capital

£000

 

Total

£000

 

Revenue

£000

Capital

£000

Total

£000

 

Final paid - 2.0p per share paid 22 May 2012

 

341

 

425

 

766

 

-

 

-

 

-

 

-

-

 

-

 

Final paid - 2.0p per share paid 10 June 2011

 

-

 

-

 

-

 

-

 

468

 

468

 

-

468

 

468

 

Interim paid - 2.0p per share paid 30 September 2011

 

-

 

-

 

-

 

-

 

-

 

-

-

469

469

 

341

425

766

-

468

468

-

937

937

 

 

 

An interim dividend of 2.5 pence per Ordinary Share, amounting to £956,093, is proposed. The dividend has not been recognised in these half year financial statements as the obligation did not exist at the balance sheet date.

 

 

5. Basic and Diluted Earnings per Ordinary Share

The basic and diluted earnings per Ordinary Share is based on the profit after tax attributable to equity Shareholders of £849,000 (30 June 2011: profit of £475,000) and 35,885,606 (30 June 2011: 20,367,889) Ordinary shares being the weighted average number of Ordinary shares in issue during the period.

 

The basic and diluted revenue return per Ordinary Share is based on the revenue profit attributable to equity Shareholders of £47,000 (30 June 2011: £2,000) and 35,885,606 (30 June 2011: 20,367,889) Ordinary shares being the weighted average number of Ordinary shares in issue during the period.

 

The basic and diluted capital return per Ordinary Share is based on the capital profit attributable to equity Shareholders of £802,000 (30 June 2011: profit of £473,000) and 35,885,606 (30 June 2011: 20,367,889) Ordinary shares being the weighted average number of Ordinary shares in issue during the period.

 

During the period the Company allotted 20,611 new Ordinary shares in respect of its dividend reinvestment scheme and 5,080,416 new Ordinary shares under the "Offer for Subscription". A further 158,303 new Ordinary shares were allotted to an existing individual Shareholder.

The Company has repurchased 249,234 of its own shares in the period and these shares are held in treasury. The total of 1,178,356 treasury shares has been excluded in calculating the weighted average number of Ordinary shares during the year. The Company has no securities that would have a dilutive effect and hence basic and diluted earnings per Ordinary Share are the same.

 

 

6. Basic and Diluted Net Asset Value per Ordinary Share

The basic and diluted Net Asset Value per Ordinary Share is calculated on attributable assets of £26,004,000 (30 June 2011 and 31 December 2011: £15,888,000 and £15,982,000 respectively) and 38,243,718 (30 June 2011 and 31 December 2011: 23,359,278 and 23,330,802 respectively) Ordinary shares in issue at the year end.

 

The 1,178,356 (30 June 2011: 757,380) treasury shares have been excluded in calculating the number of Ordinary shares in issue at 30 June 2012. The Company has no securities that would have a dilutive effect and hence basic and diluted Net Asset Value per Ordinary share are the same.

 

 

7. Total Return

Total Return per share is calculated on cumulative dividends paid of 32.0 pence per Ordinary Share (30 June 2011: 28.0 pence per Ordinary share and 31 December 2011: 30.0 pence per Ordinary share) plus the Net Asset Value as calculated in note 6.

 

 

8. Directors

The directors of the Company are: Mr R Last, Mr R M Pettigrew, and Mr P C Waller.

 

 

 

9. Other Information

 

Copies of the interim report can be obtained from the Company's registered office: Saint Martins House, 210-212 Chapeltown Road, Leeds, LS7 4HZ or from the fund manager's website: www.yfmep.com.

 

 

Advisers to the Company

 

Directors Registrars

Richard Last

Robert Martin Pettigrew

Peter Charles Waller

 

Stockbrokers

Singer Capital Markets

One Hanover Street

London

W1S 1AX

 

Fund Manager

YFM Private Equity Limited

Saint Martins House

210-212 Chapeltown Road

Leeds

LS7 4HZ

 

Fixed Interest Securities Adviser

Brewin Dolphin Securities Limited

34 Lisbon Street

Leeds

LS1 4LX

 

Registrars

Capita Registrars

The Registry

34 Beckenham Road

Beckenham

Kent

BR3 4BR

 

Independent Auditor

Grant Thornton UK LLP

2 Broadfield Court

Sheffield

S8 0XF

 

Solicitors

hlw Keeble Hawson LLP

Protection House

16-17 East Parade

Leeds

LS1 2BR

 

VCT Status and Tax Adviser

PricewaterhouseCoopers LLP

1 Embankment Place

London

WC2N 6RH

 

 

Secretary and Registered Office

KHM Secretarial Services Limited

Old Cathedral Vicarage

St James RowSheffield

S1 1XA

Bankers

The Royal Bank of Scotland plc

27 Park Row

Leeds

LS1 5QB

 

 

 

 

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IR DMGZRLLRGZZG
Date   Source Headline
3rd Apr 20248:04 amRNSDirector/PDMR Shareholding
3rd Apr 20248:04 amRNSDirector/PDMR Shareholding
3rd Apr 20247:57 amRNSIssue of Equity and Close of Offers
26th Mar 202411:10 amRNSTransaction in Own Shares and Total Voting Rights
21st Mar 20247:40 amRNSAppointment of non-executive Director
20th Mar 202412:00 pmRNSPublication of Supplementary Prospectus
20th Mar 202412:00 pmRNSPublication of Supplementary Prospectus
15th Mar 202412:15 pmRNSAnnual Financial Report
16th Feb 20243:52 pmRNSClose of Offers to New Applications
16th Feb 20243:51 pmRNSClose of Offers to New Applications
30th Jan 20249:26 amRNSDirector/PDMR Shareholding
30th Jan 20249:24 amRNSDirector/PDMR Shareholding
30th Jan 20249:24 amRNSIssue of Equity
18th Dec 20234:04 pmRNSTransaction in Own Shares
13th Dec 20234:00 pmRNSOffer Update
13th Dec 20234:00 pmRNSStrategy/Company/Ops Update
24th Nov 20237:00 amRNS3rd Quarter Results
3rd Nov 20239:40 amRNSPayment of dividend and issue of equity
24th Oct 20231:20 pmRNSOffer Update
24th Oct 20231:19 pmRNSOffer Update
6th Oct 202310:19 amRNSOffer Update
6th Oct 202310:17 amRNSOffer Update
27th Sep 20238:21 amRNSOffer Update
26th Sep 20238:16 amRNSTransaction in Own Shares
20th Sep 202312:30 pmRNSPublication of a Prospectus
20th Sep 202312:30 pmRNSPublication of a Prospectus
13th Sep 20237:00 amRNSHalf-year Report
2nd Aug 202310:25 amRNSNew combined offer for subscription
2nd Aug 202310:25 amRNSNew combined offer for subscription
27th Jun 20237:46 amRNSTransaction in Own Shares
26th Jun 202310:57 amRNSDirector/PDMR Shareholding
26th Jun 202310:56 amRNSPayment of Dividend and Issue of Equity
16th Jun 202312:00 pmRNS1st Quarter Results
15th Jun 20233:17 pmRNSResult of Meeting
15th Jun 20233:16 pmRNSResult of AGM
4th Apr 20233:25 pmRNSDirector/PDMR Shareholding
4th Apr 20233:25 pmRNSDirector/PDMR Shareholding
4th Apr 20233:24 pmRNSDirector/PDMR Shareholding
4th Apr 20233:22 pmRNSIssue of Equity and Close of Offers
29th Mar 20238:40 amRNSTransaction in Own Shares
27th Mar 20236:00 pmRNSClose of Offers to new Applications
27th Mar 20236:00 pmRNSClose of Offers to new Applications
23rd Mar 202311:30 amRNSPublication of Circular
22nd Mar 202312:15 pmRNSPublication of Supplementary Prospectus
22nd Mar 202312:15 pmRNSPublication of Supplementary Prospectus
20th Mar 20233:00 pmRNSAnnual Financial Report
14th Feb 20234:35 pmRNSOffer Update
14th Feb 20234:35 pmRNSOffer Update
11th Jan 202310:00 amRNSPayment of Dividend and Issue of Equity
19th Dec 20228:50 amRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.